An assessment of donor-to-recipient transmission patterns of human cytomegalovirus by analysis of viral genomic variants

Journal of Infectious Diseases

Volumn 199, Issue 11, 2009, Pages 1621-1628

  Manuel, Oriol ^a,b   Pang, Xiaoli L ^a   Humar, Atui ^a   Kumar, Deepali ^a   Doucette, Karen ^a   Preiksaitis, Jutta K ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; GLYCOPROTEIN B; VALGANCICLOVIR; VIRUS GLYCOPROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; FEMALE; GENOME ANALYSIS; GENOTYPE; GRAFT RECIPIENT; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMAN TISSUE; MALE; MIXED INFECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; ORGAN DONOR; ORGAN DONOR RECIPIENT TRANSMISSION; ORGAN TRANSPLANTATION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; SEROPREVALENCE; VIREMIA; VIRUS GENOME; VIRUS LOAD; VIRUS REACTIVATION; VIRUS STRAIN; VIRUS TRANSMISSION;

ADULT; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA PRIMERS; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC;

EID: 67650671190     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/598952     Document Type: Article

References (21)

1. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357:2601-14.
2. Cytomegalovirus. Am J Transplant 2004; 4(Suppl 10):51-8.
3. Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999; 340:1462-70.
4. Razonable RR. Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients. Am J Health Syst Pharm 2005; 62(Suppl 1):S7-13.
5. Razonable RR, Rivero A, Rodriguez A, et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 2001; 184:1461-4.
6. Grundy JE, Lui SF, Super M, et al. Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus. Lancet 1988; 332:132-5.
7. Chou SW. Acquisition of donor strains of cytomegalovirus by renaltransplant recipients. N Engl J Med 1986; 314:1418-23.
8. Chou SW. Reactivation and recombination of multiple cytomegalovirus strains from individual organ donors. J Infect Dis 1989; 160:11-5.
9. Chou SW. Cytomegalovirus infection and reinfection transmitted by heart transplantation. J Infect Dis 1987; 155:1054-6.
10. Chou SW, Norman DJ. The influence of donor factors other than serologic status on transmission of cytomegalovirus to transplant recipients. Transplantation 1988; 46:89-93.
11. Boehme KW, Singh J, Perry ST, Compton T. Human cytomegalovirus elicits a coordinated cellular antiviral response via envelope glycoprotein B. J Virol 2004; 78:1202-11.
12. Navarro D, Paz P, Tugizov S, Topp K, La Vail J, Pereira L. Glycoprotein B of human cytomegalovirus promotes virion penetration into cells, transmission of infection from cell to cell, and fusion of infected cells. Virology 1993; 197:143-58.
13. Coaquette A, Bourgeois A, Dirand C, Varin A, Chen W, Herbein G. Mixed cytomegalovirus glycoprotein B genotypes in immunocompromised patients. Clin Infect Dis 2004; 39:155-61.
14. Humar A, Kumar D, Gilbert C, Boivin G. Cytomegalovirus (CMV) glycoprotein B genotypes and response to antiviral therapy, in solid-organtransplant recipients with CMV disease. J Infect Dis 2003; 188:581-4.
15. Shepp DH, Match ME, Ashraf AB, Lipson SM, Millan C, Pergolizzi R. Cytomegalovirus glycoprotein B groups associated with retinitis in AIDS. J Infect Dis 1996; 174:184-7.
16. Pang XL, Humar A, Preiksaitis JK. Concurrent genotyping and quantitation of cytomegalovirus gB genotypes in solid organ transplant recipients using a real-time PCR assay. J Clin Microbiol 2008; 46:4004-10.
17. Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. AST ID Working Group on Infectious Disease Monitoring. Am J Transplant 2006; 6:262-74.
18. Gourishankar S, McDermid JC, Jhangri GS, Preiksaitis JK. Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive era. Am J Transplant 2004;4:108-15.
19. Preiksaitis JK, Sandhu J, Strautman M. The risk of transfusion-acquired CMV infection in seronegative solid organ transplant recipients receiving nonleukoreduced blood products not screened for CMV antibody (1984-1996): experience at a single Canadian center. Transfusion 2002; 42:396-402.
20. Preiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian Society of Transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005; 5: 218-27.
21. Rosen HR, Corless CL, Rabkin J, Chou S. Association of cytomegalovirus genotype with graft rejection after liver transplantation. Transplantation 1998; 66:1627-31.